Arch Therapeutics, Inc. (OTCMKTS:ARTH – Get Free Report) saw a large decline in short interest during the month of April. As of April 30th, there was short interest totalling 12,400 shares, a decline of 5.3% from the April 15th total of 13,100 shares. Based on an average trading volume of 4,300 shares, the short-interest ratio is presently 2.9 days.
Arch Therapeutics Price Performance
Shares of Arch Therapeutics stock opened at $1.04 on Friday. Arch Therapeutics has a 52-week low of $0.39 and a 52-week high of $18.00. The company has a fifty day moving average of $1.51 and a 200-day moving average of $3.34.
Arch Therapeutics (OTCMKTS:ARTH – Get Free Report) last issued its earnings results on Tuesday, February 20th. The biotechnology company reported ($0.57) earnings per share for the quarter. The company had revenue of $0.05 million during the quarter.
About Arch Therapeutics
Arch Therapeutics, Inc, together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease.
Read More
- Five stocks we like better than Arch Therapeutics
- What Are Dividends? Buy the Best Dividend Stocks
- Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
- Dividend Payout Ratio Calculator
- Analysts Still Want Double-Digit Upside Out of Applied Materials
- What Are the U.K. Market Holidays? How to Invest and Trade
- Baidu Stock Earnings Prove Ray Dalio Right about China?
Receive News & Ratings for Arch Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
